The PrognosticRole of Tumor Marker CA-125 in B-Cell

Bahram Memar; Seyed Amir Aledavood; Soodabeh Shahidsales; Mitr Ahadi; Mahdi Farzadnia; Hamid Reza Raziee; Sedighe Noori; Naser Tayebi-Meybodi; Sakineh Amouian; Samira Mohtashami

International Journal of Cancer Management

The Official Journal of Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences

Outlines

Abstract
Copyright

The PrognosticRole of Tumor Marker CA-125 in B-Cell

Author(s):

Bahram Memar¹,

Seyed Amir Aledavood^2,*,

Soodabeh Shahidsales²,

Mitr Ahadi³,

Mahdi Farzadnia⁴,

Hamid Reza Raziee²,

Sedighe Noori⁵,

Naser Tayebi-Meybodi⁴,

Sakineh Amouian⁴,

Samira Mohtashami²

1Surgical Oncology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2Cancer Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3Dept. of Internal, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4Dept. of Pathology, Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

5Medical Student, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

International Journal of Cancer Management:Vol. 8, issue 1; e80580

Published online:Feb 28, 2015

Article type:Research Article

Received:May 01, 2014

Accepted:Oct 25, 2014

How to Cite:Bahram MemarSeyed Amir AledavoodSoodabeh ShahidsalesMitr AhadiMahdi FarzadniaHamid Reza RazieeSedighe NooriNaser Tayebi-MeybodiSakineh AmouianSamira Mohtashamiet al.The PrognosticRole of Tumor Marker CA-125 in B-Cell.Int J Cancer Manag.8(1):e80580.

Abstract

Background: B-cell non-Hodgkin’s lymphoma (NHL) is a common malignancy of lymphoid tissues. Different types of NHL show various behaviors, prognoses, and responses to treatment. Evaluation of disease activity in NHL can be helpful in managing and even increasing the patient’s survey.

Methods and Results: In total, 121 patients (76 males and 45 females), and their age range were 18-53 years, were evaluated in this study. The mean level of serum carbohydrate antigen 125 (CA-125) was 89.3±18.5 u/ml, ranging from 27 to 135 u/ml. There were significant differences in International Prognostic Index (IPI) score (p=0.002), stage of the disease (p=0.006), mortality rate (p=0.02), and relapse rate (p=0.04) between patients with serum CA-125 level 35 u/ml.

Conclusion: CA-125 seems to be a useful and reliable tumor marker for monitoring a patient with NHL. It might be the time to consider CA-125 in staging, prognostic scoring, or decision making about NHL treatment.

Keywords

B cell non-Hodgkin’s lymphoma (NHL)

tumor marker

CA-125

mortality rate

Fulltext

The Full text is available in PDF.

comments